Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer
Jia-Yang Cai, Min-Ying Huang, Shao-Ying Yang, Fang-Lin Zhang, Yin-Ling Zhang, Lisa Andriani, Qian Zhao, A-Yong Cao, Da-Qiang Li, Zhi-Ming Shao · 2026
Read Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer by Jia-Yang Cai, Min-Ying Huang, Shao-Ying Yang, Fang-Lin Zhang, Yin-Ling Zhang, Lisa Andriani, Qian Zhao, A-Yong Cao, Da-Qiang Li, Zhi-Ming Shao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13507113.txt.
Description
Jia-Yang Cai leads a 2026 team that uncovers a non-enzymatic role for NANS, a sugar-making enzyme, in hormone-sensitive breast cancer. This common cancer type often stops responding to hormone therapy and to CDK4/6 blocker drugs. Tumors with high NANS levels grew faster and resisted both drug types, and patients fared worse.
NANS protected another protein, LATS2, by recruiting a cleanup blocker called USP7, which kept LATS2 from being destroyed. Stable LATS2 then raised hormone receptor and CDK4 levels through a growth pathway. Restoring LATS2 partly revived growth and resistance after NANS loss, in dishes and in mice. Patient samples supported the same chain, which marks NANS as a drug target.
Catalog record
| CREATOR | Jia-Yang Cai, Min-Ying Huang, Shao-Ying Yang, Fang-Lin Zhang, Yin-Ling Zhang, Lisa Andriani, Qian Zhao, A-Yong Cao, Da-Qiang Li, Zhi-Ming Shao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 109581 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |